AIMT - アイミュ―ン・セラピュ―ティクス (Aimmune Therapeutics Inc.) アイミュ―ン・セラピュ―ティクス

 AIMTのチャート


 AIMTの企業情報

symbol AIMT
会社名 Aimmune Therapeutics Inc (アイミュ―ン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アイミューン・セラピューティクス(Aimmune Therapeutics Inc.)はピーナッツおよび他の食物アレルギーの治療用、製品候補の開発を含む治療アプローチを開発する臨床段階のバイオ医薬品会社である。特徴的な経口脱感作免疫療法(CODIT)と呼ばれる同社の治療アプローチは、特徴付けられた生物学的製剤、定義された治療プロトコールおよび支援サービスを使用して、患者を食物アレルゲンに対して脱感作するように設計されたシステムである。同社のCODIT製品候補であるAR101は、ピーナッツアレルギーの患者の治療用治験薬である。同社は、AR101のフェーズⅢ登録試験である小児および成人の脱感作(PALISADE)のためのAR101のピーナッツアレルギー経口免疫療法研究を開始した。同社はメンテナンスフェーズにおいて、AR101の追加配達フォームを評価している。   アイミュ―ン・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、主にピ―ナッツなどの食品アレルギ―治療薬の開発、商品化に従事する。治療のアプロ―チは、バイオ薬剤で患者をアレルギ―の元である特定食品に対する反応を抑制させることによる。薬剤製品候補の「AR101」は、ピ―ナッツのたんぱく質に対する反応を鈍化させる。本社はカリフォルニア州。   Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
本社所在地 8000 Marina Blvd. #300 Brisbane CA 94005 USA
代表者氏名 Mark D. McDade マークD.マクダード
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-614-5220
設立年月日 40695
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 131人
url www.aimmune.com
nasdaq_url https://www.nasdaq.com/symbol/aimt
adr_tso
EBITDA EBITDA(百万ドル) -176.54400
終値(lastsale) 26.18
時価総額(marketcap) 1530939379.2
時価総額 時価総額(百万ドル) 1531.524
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1241.524
当期純利益 当期純利益(百万ドル) -148.11000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aimmune Therapeutics Inc revenues was not reported. Net loss increased 75% to $102.1M. Higher net loss reflects Research and Development - other increase of 60% to $49.8M (expense) Employee-related costs increase from $6.4M to $13.9M (expense) General and Administrative - other increase of 81% to $14.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.16 to -$1.83.

 AIMTのテクニカル分析


 AIMTのニュース

   This 39-year-old with a mission to change the business of medicine left McKinsey after one piece of advice upended her entire strategy  2020/10/01 16:50:44 Business Insider
Summary List Placement Mary Rozenman initially set out to be a doctor, after watching her sister deal with uncontrolled epilepsy throughout her childhood. But she realized in college, that blood made her cringe. Instead, Rozenman got her doctorate in organic chemistry and chemical biology from Harvard University. Then as a 26-year-old working under David Liu, a gene-editing pioneer, something about drug development didn't sit right with the young chemist. Among the thousands of new discoveries each year, just a small handful of them make it through the "funnel," she said. "I envisioned a funnel, where you have at the top of the funnel all of these amazing discoveries and innovations that sort of move through the system," Rozenman told Business Insider. "And somehow only a small handful of them get filtered into medicines that actually make it out into the real world's drug supply," she said. Rozenman needed to understand how that funnel works, she said. What happened behind the scenes to squelch each year's hundreds of thousands of breakthroughs, and where did the money come from to advance some things and not others?
   Allergy Immunotherapies Market Significance, Overview, and Worldwide Outlook By ALK-Abelló A/S, AIMMUNE THERAPEUTICS, INC., LETIPharma, Stallergenes Greer, HAL Allergy B.V, Anergis,  2020/10/01 14:18:57 OpenPR
A report by The Insight Partner's on the Allergy Immunotherapies Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT  2020/09/19 00:00:00 Benzinga
NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own. … Full story available on Benzinga.com
   Nestlé Launches $2.6B Tender Offer For Aimmune Therapeutics  2020/09/14 08:48:47 Smarter Analyst
Nestlé S.A. The post Nestlé Launches $2.6B Tender Offer For Aimmune Therapeutics appeared first on Smarter Analyst .
   Nestle initiates tender offer for Aimmune Therapeutics (OTCMKTS:NSRGY)  2020/09/14 06:28:00 Seeking Alpha
Nestle (OTCPK:NSRGY) subsidiary Société des Produits Nestlé S.A. (SPN) is commencing today a cash tender offer to purchase all of the outstanding common sh
   Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/07 12:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
   Why Shares of Aimmune Are Trading Higher While DBV Plunges  2020/08/04 15:05:34 Benzinga
Aimmune Therapeutics Inc (NASDAQ: AIMT ) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains. The Aimmune Catalyst: Shares of Brisbane, California-based Aimmune — which has a commercial product in Palforzia, used to treat peanut allergy in patients ages 4-17 — are moving in sympathy with DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ). DBV faces a regulatory setback, as the FDA handed down a complete response letter to its BLA for Viaskin Patch, an epicutaneous patch to treat peanut allergies in children ages 4-11. The decision has been expected since the FDA's decision to cancel an Adcom meeting scheduled for May 15. The nature … Full story available on Benzinga.com
   Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights  2020/07/30 20:05:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights  2020/07/23 12:30:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
   Best Stocks for 2020: Expect Aimmune Stock to Come Back in Full Force  2020/07/02 16:01:23 InvestorPlace
Aimmune Therapeutics may be struggling now in the Best Stocks contest, but the future is still bright for AIMT stock thanks to Palforzia.
   Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights  2020/02/27 21:05:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
   Aimmune Therapeutics to Present at Upcoming Investor Conferences  2020/02/26 13:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at Upcoming Investor Conferences
   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights  2020/02/20 13:30:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational
   What's in Store for Aimmune (AIMT) This Earnings Season?  2020/02/19 15:13:00 Zacks Investment Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
   Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment  2020/02/06 15:50:48 Benzinga
Aimmune Therapeutics Inc (NASDAQ: AIMT ) recently received FDA approval for its peanut allergy drug Palforzia. The Aimmune Analyst Baird analyst Brian Skorney maintained an Outperform rating on Aimmune with a $64 price target. The Aimmune Thesis With NESTLE S A/S ADR (OTC: NSRGY ) Health Science's $200-million investment in Aimmune, the company is now adequately funded for the Palforzia launch, settling the bull-bear launch debate, Skorney said in a Thursday note. (See his track record here .) The Nestle investment, along with Aimmune's existing cash and KKR credit facility, places more than $450 million at Aimmune's disposal, the analyst said. "Given this significant liquidity, we do not believe the company will need to raise additional capital in the near-term, essentially eliminating the ability … Full story available on Benzinga.com

 関連キーワード  (医薬品 米国株 アイミュ―ン・セラピュ―ティクス AIMT Aimmune Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)